UPDATE: MLV & Co Reiterates On Galectin Therapeutics Following Cohort 2 Results

By: via Benzinga
In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galectin Therapeutics (NASDAQ: GALT), ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.